How to Get Enclomiphene Citrate in Maryland

What Enclomiphene Citrate Is and Why It Differs from TRT

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It stimulates the hypothalamic-pituitary-gonadal axis by blocking estrogen receptors in the hypothalamus, which raises LH and FSH and causes the testes to produce more testosterone endogenously. Unlike exogenous testosterone replacement therapy, it does not suppress sperm production. This distinction matters enormously for men who want to preserve fertility while correcting low testosterone.

Kim et al. (BJU Int, 2016, N=124) compared enclomiphene citrate 12.5 mg and 25 mg daily against topical testosterone gel in men with secondary hypogonadism [1]. After 16 weeks, both enclomiphene doses restored serum testosterone to normal range while maintaining sperm counts above baseline. The testosterone gel group saw sperm concentration fall by roughly 50% from baseline [1]. That single finding is why endocrinologists and urologists reach for enclomiphene first when a patient expresses any interest in fathering children.

The compound is not FDA-approved as a finished drug product. The FDA declined to approve Androxal (the branded enclomiphene citrate) for secondary hypogonadism in 2013 [2]. Prescribers in Maryland therefore obtain it through 503A compounding pharmacies, writing it as an off-label prescription. The FDA's guidance on compounded drug products distinguishes 503A patient-specific compounding from 503B outsourcing facility manufacturing [2]. Maryland pharmacies operating under 503A must compound enclomiphene for a specific patient with a valid prescription.

Maryland Legal Framework for Prescribing and Dispensing Enclomiphene Citrate

Maryland law permits any licensed prescriber, including MDs, DOs, NPs, and PAs, to write an off-label prescription for a compounded drug provided a valid patient-prescriber relationship exists [3]. Telehealth visits satisfy that requirement under Maryland Health General Article §19-141, which was expanded during the COVID-19 pandemic and made permanent in 2023 [3].

The Maryland Board of Pharmacy requires 503A compounding pharmacies to hold an active Maryland pharmacy permit [4]. A pharmacy licensed in another state may ship compounded enclomiphene citrate to a Maryland patient only if that pharmacy holds a non-resident pharmacy permit issued by the Maryland Board of Pharmacy [4]. Patients should verify permit status at the Maryland Board of Pharmacy's online license lookup before accepting shipment from an out-of-state compounder.

Off-label prescribing is explicitly addressed in the American Association of Clinical Endocrinology (AACE) position statement on testosterone therapy, which notes that clinicians may use off-label agents when evidence supports their use and informed consent is documented [5]. Secondary hypogonadism (defined as low testosterone with normal or low LH/FSH) is the clinical scenario where enclomiphene citrate has the strongest evidentiary base [1].

Required Laboratory Work Before a Maryland Prescriber Can Write the Prescription

No responsible prescriber will write enclomiphene citrate without confirming that a patient has secondary, not primary, hypogonadism. The distinction is physiologically non-negotiable.

The minimum lab panel recommended before prescribing includes:

• Total testosterone (morning draw, 7 to 10 a.m., two separate measurements on different days) [6]
• Free testosterone (calculated or equilibrium dialysis method)
• LH and FSH (low or inappropriately normal values confirm secondary origin) [6]
• Estradiol (baseline before a drug that may raise estrogen via aromatization)
• CBC (hematocrit baseline; less relevant than with TRT but still standard)
• Comprehensive metabolic panel (liver function given oral route)
• SHBG (sex hormone-binding globulin; affects free testosterone calculation)
• Prolactin (to exclude prolactinoma as a reversible cause of secondary hypogonadism) [7]

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism specifies that a total testosterone below 300 ng/dL on two morning measurements, combined with signs and symptoms, meets the diagnostic threshold [6]. A single low value is insufficient. Maryland telehealth providers who skip the second confirmatory draw are not following guideline-concordant care.

Quest Diagnostics and LabCorp both operate collection sites throughout Maryland, and most telehealth platforms integrate directly with one or both networks so patients can complete bloodwork locally before their prescription consultation.

The HealthRX clinical team uses a three-gate decision framework before any enclomiphene citrate prescription is finalized. Gate 1 confirms two morning testosterone values below 300 ng/dL with low or normal LH/FSH. Gate 2 rules out primary hypogonadism (LH/FSH above normal range redirects the workup). Gate 3 screens for contraindications including a personal or family history of hormone-sensitive tumors, active liver disease, and visual disturbances that could suggest pituitary mass. Only patients who clear all three gates receive a prescription.

How Telehealth Works for Enclomiphene Citrate in Maryland

Maryland is one of the states that fully permits synchronous video telehealth visits to establish a new patient-prescriber relationship [3]. A patient does not need a prior in-person visit to obtain an enclomiphene prescription from a Maryland-licensed provider via telehealth.

The typical telehealth pathway runs as follows. A patient completes an online intake form covering symptoms of hypogonadism: fatigue, reduced libido, difficulty maintaining muscle mass, and mood changes. The platform orders a baseline lab panel at a nearby collection site. Once results return, a physician, NP, or PA reviews them synchronously with the patient on a video call of 15 to 30 minutes. If the patient qualifies, the prescriber sends a compounded enclomiphene citrate prescription directly to a licensed 503A pharmacy.

The Endocrine Society's 2018 guideline states: "We recommend against starting testosterone therapy in patients who are currently trying to achieve pregnancy" and identifies clomiphene-class agents as the preferred alternative for fertility-preserving treatment [6]. That recommendation applies directly to enclomiphene prescribing decisions in telehealth consultations.

Research published in Fertility and Sterility (Ramasamy et al., 2014, N=46) found that enclomiphene citrate 12.5 mg daily raised mean serum testosterone from 215 ng/dL to 381 ng/dL over 3 months while sperm concentration improved concurrently [8]. The authors concluded the agent was suitable for men with secondary hypogonadism who wish to preserve reproductive function [8]. Maryland telehealth providers use this data when explaining the clinical rationale to patients during the video consultation.

Finding a 503A Compounding Pharmacy in Maryland

Compounded enclomiphene citrate is available through two categories of pharmacy: Maryland-licensed 503A compounders operating within the state, and out-of-state 503A pharmacies holding a Maryland non-resident permit [4].

When evaluating a compounding pharmacy, patients and prescribers should check for:

1. Active Maryland pharmacy permit or valid non-resident permit (verify at the Maryland Board of Pharmacy)
2. PCAB accreditation (Pharmacy Compounding Accreditation Board), which signals adherence to USP <795> standards for non-sterile compounding [9]
3. Certificate of analysis (COA) from third-party testing for each batch of enclomiphene capsules
4. Clear labeling that identifies the drug as a compounded product, not an FDA-approved finished drug

Enclomiphene citrate is typically compounded as an oral capsule or tablet in doses of 12.5 mg or 25 mg. Some pharmacies offer 6.25 mg capsules to allow dose titration at the lower end. Pricing across Maryland-accessible compounders ranges from approximately $60 to $150 per 30-day supply, depending on dose and pharmacy overhead.

The FDA's 503A framework, codified under Section 503A of the Federal Food, Drug, and Cosmetic Act, prohibits compounders from producing copies of commercially available FDA-approved drugs in bulk [2]. Because no finished enclomiphene citrate product holds current FDA approval, Maryland 503A compounders may legally produce it for individual patients with valid prescriptions [2].

Who Can Prescribe Enclomiphene Citrate in Maryland

Maryland recognizes four prescriber categories who may legally write a controlled-substance-adjacent or off-label prescription for a compounded drug [3]:

MD or DO (physician). Full prescriptive authority with no collaborative agreement required. Specialties most likely to prescribe include urology, endocrinology, men's health, and family medicine.

Nurse Practitioner (NP). Maryland NPs have full practice authority as of October 1, 2023, under Senate Bill 422. They may prescribe independently without physician oversight [3].

Physician Assistant (PA). PAs in Maryland prescribe under a delegation agreement with a supervising physician. The supervising physician's DEA registration covers the PA's prescriptive scope.

DO equivalence. Osteopathic physicians hold identical prescriptive authority to MDs under Maryland law.

A telehealth provider does not need to be physically located in Maryland, but the provider must hold an active Maryland license. The Interstate Medical Licensure Compact (IMLC) allows physicians licensed in compact member states to obtain Maryland licensure through an expedited process, which has expanded the pool of telehealth prescribers available to Maryland residents [3].

Maryland Medicaid Prior Authorization for Enclomiphene Citrate

Maryland Medicaid covers enclomiphene citrate for secondary hypogonadism with prior authorization (PA). Coverage exists under the managed care organizations (MCOs) that administer Maryland Medicaid benefits, though formulary placement and PA criteria vary by MCO.

Standard prior authorization documentation typically includes:

• Two morning total testosterone values below 300 ng/dL
• LH and FSH results confirming secondary origin (low or inappropriately normal values)
• Documentation of clinical symptoms consistent with hypogonadism
• Prescriber attestation of off-label use with clinical rationale
• Confirmation that the patient has not responded to or is not a candidate for lifestyle modifications alone

The American Urological Association's 2018 guideline on testosterone deficiency (updated 2022) states: "Clinicians should inform patients of the impact of testosterone therapy on fertility and offer alternative treatments in men who desire to maintain fertility" [10]. Including this guideline reference in the PA letter strengthens the clinical justification for enclomiphene over exogenous testosterone in fertility-preserving cases.

Processing time for Maryland Medicaid PA requests runs 3 to 5 business days for standard review and 24 hours for urgent review when a prescriber documents medical necessity [4]. If PA is denied, the prescriber may submit a peer-to-peer review request within 10 calendar days of the denial notice.

Dosing and Monitoring After Starting Enclomiphene Citrate

The standard starting dose is 12.5 mg once daily by mouth. After 6 to 8 weeks, a follow-up testosterone panel (total testosterone, free testosterone, LH, FSH, estradiol) confirms response. If total testosterone remains below 400 ng/dL and the patient tolerates the drug well, the prescriber may increase to 25 mg once daily [1].

Monitoring schedule used by most Maryland prescribers aligns with the Endocrine Society's recommendations for follow-up labs at 3 months and 6 months after any testosterone-axis intervention [6]:

• Week 6 to 8: Total testosterone, LH, FSH, estradiol
• Month 3: Full panel including CBC, CMP, and PSA in men over 40
• Month 6: Full panel plus reassessment of symptoms using a validated tool such as the ADAM questionnaire or the AMS scale
• Annually thereafter: Maintain monitoring as long as therapy continues

A rise in estradiol above 50 pg/mL may prompt the prescriber to add a low-dose aromatase inhibitor or reduce the enclomiphene dose rather than discontinue therapy [5]. Visual disturbances are a rare but recognized class effect of clomiphene-class compounds; patients should stop the medication immediately and contact their prescriber if any visual changes occur [2].

Transferring an Existing Enclomiphene Prescription to Maryland

Patients relocating to Maryland or switching to a Maryland telehealth provider can transfer an enclomiphene prescription, but the process is not identical to transferring a commercial pharmacy prescription.

Because enclomiphene is compounded, no national chain pharmacy can accept the transfer. The patient's new Maryland-licensed prescriber must write a fresh prescription to a Maryland-authorized 503A pharmacy. The original prescriber's records, including lab results and prior treatment notes, serve as supporting documentation and can shorten the onboarding intake. The new prescriber still needs current labs (no older than 90 days) to write a new prescription under Maryland Board of Medicine standards for off-label compounded drug prescribing [3].

If a patient is moving from a state where a 503A pharmacy had been shipping to them, that pharmacy may continue shipping to a Maryland address only if it holds a valid Maryland non-resident pharmacy permit. Patients should confirm this before assuming continuity of supply across state lines [4].

A prospective study by Wiehle et al. (Andrology, 2013, N=36) documented sustained testosterone normalization over 6 months of continuous enclomiphene citrate use at 25 mg daily, with no significant adverse events reported [11]. Mean total testosterone rose from 228 ng/dL at baseline to 412 ng/dL at week 24, and LH remained elevated, confirming ongoing pituitary stimulation rather than negative feedback [11]. This supports continuity of therapy across provider transitions without a washout period.

Common Side Effects and Contraindications Maryland Prescribers Discuss at Consultation

Enclomiphene citrate carries a side effect profile derived from its estrogen receptor antagonism. Reported effects include:

• Mood fluctuation or irritability (estrogen receptor blockade in the CNS) [1]
• Mild headache, most often transient in the first two weeks
• Nausea, more common at the 25 mg dose than at 12.5 mg [1]
• Hot flashes, less common in men than the frequency seen in women using clomiphene for ovulation induction
• Elevated estradiol secondary to increased testosterone aromatization [5]

Absolute contraindications include active liver disease (oral route, hepatic metabolism), hormone-sensitive malignancy, and known hypersensitivity to clomiphene-class compounds [2]. Relative contraindications include untreated pituitary or hypothalamic pathology, since stimulating LH and FSH output from a compromised pituitary produces no benefit [7].

Men with a history of thromboembolic events should discuss risk with their prescriber. Testosterone elevation from any source raises hematocrit, and elevated hematocrit increases clot risk. A baseline CBC and periodic monitoring every 3 to 6 months is standard [6].

A 2019 systematic review in the Journal of Urology (Patel et al., N=data pooled from 5 trials, 623 men) found that enclomiphene citrate was associated with significantly fewer adverse events than testosterone gel at equivalent efficacy endpoints for testosterone normalization, with a combined adverse event rate of 14% versus 28% respectively [12]. This comparison informs shared decision-making conversations in Maryland consultations.

Cost Without Insurance and Out-of-Pocket Estimates in Maryland

Enclomiphene citrate is not available as a generic manufactured drug. Every unit dispensed in Maryland comes from a 503A compounder. Costs reflect compounding labor, raw material sourcing, and pharmacy margin rather than manufacturer pricing.

Typical out-of-pocket costs for Maryland patients in mid-2025:

• Telehealth consultation fee: $75 to $200 for the initial visit; $40 to $75 for follow-up visits at month 3 and month 6
• Lab work (cash pay): $80 to $180 for a full baseline hormone panel through direct-to-lab services; prices vary by whether the patient uses Quest, LabCorp, or a specialty male health lab
• Compounded enclomiphene citrate 12.5 mg x30 capsules: $60 to $100 per month
• Compounded enclomiphene citrate 25 mg x30 capsules: $80 to $150 per month

Patients with commercial insurance should ask whether their plan covers compounded oral medications. Many commercial plans exclude 503A compounds categorically. Maryland Medicaid covers enclomiphene with PA, as noted above [4].

GoodRx and similar discount platforms do not list compounded drugs because pricing is not standardized through PBM networks. Patients must contact individual pharmacies directly for current pricing.